Literature DB >> 21299740

Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials.

K Fischer1, P Collins, S Björkman, V Blanchette, M Oh, S Fritsch, P Schroth, G Spotts, B Ewenstein.   

Abstract

Replacement therapy or prophylaxis, has become the standard of care for the treatment of severe haemophilia A. To describe bleeding patterns in children, adolescents and adults on prophylaxis and their observed relationships to times of infusion (during the week and during the day) as well as season of the year. Data from Advate pre-licensure prospective clinical trials from 145 patients with factor VIII (FVIII) <1%, were used. All patients underwent a 48-h pharmacokinetic study. The 10-65 year group had ≥ 75 exposure days on fixed prophylaxis (25-40 IU kg(-1) 3-4x per week). Prophylaxis was not fixed but similar for 1-6 year olds. Bleeding patterns were analysed. Overall, 700 bleeds were observed in 110/145 patients. All were treated with prophylaxis, mean dose 108 IU kg(-1) week(-1) in on average 2.9 infusions (1-6 years), 86 IU kg (-1) week(-1) in 2.7 infusions (10-17 years), and 75 IU kg (-1) week(-1) in 2.6 infusions (18-65 years), respectively. On prophylaxis, median total bleeds per year were low at 3.1 for patients aged 1-6 years, 3.3 for those aged 10-17 years and 2.1 for patients aged 18-65 years. Patients aged 1-6 years had predominantly soft tissue bleeds (79%). Incidence of joint bleeding was not associated with season, but was significantly lower in patients who infused FVIII in the mornings: median 0 per year (IQR 0.0-0.4) compared to those who infused later [median 1.8 per year (IQR 0.0-5.2)]. Older patients predominantly experienced joint bleeds (50% and 62%, respectively). More joint bleeds occurred during the summer [43 and 46% respectively, (P < 0.01)]. Bleeding patterns in patients on prophylaxis varied according to age. In addition, the 10-65 year olds showed increased bleeding during the summer. After confirmation in prospective studies, this information may be used to improve tailoring of prophylactic treatment.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21299740     DOI: 10.1111/j.1365-2516.2010.02450.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  10 in total

1.  Prophylaxis for adults with haemophilia: one size does not fit all.

Authors:  Kathelijn Fischer
Journal:  Blood Transfus       Date:  2012-04       Impact factor: 3.443

2.  MRI predicts 5-year joint bleeding and development of arthropathy on radiographs in hemophilia.

Authors:  Wouter Foppen; Irene C van der Schaaf; Frederik J A Beek; Willem P T M Mali; Kathelijn Fischer
Journal:  Blood Adv       Date:  2020-01-14

3.  Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s.

Authors:  Kathelijn Fischer; Katarina Steen Carlsson; Pia Petrini; Margareta Holmström; Rolf Ljung; H Marijke van den Berg; Erik Berntorp
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

Review 4.  Octocog alfa, antihaemophilic factor (recombinant), plasma/albumin free method (Advate®): a review of its use in the management of patients with haemophilia A.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2012-05-07       Impact factor: 9.546

5.  Targeting anticoagulant protein S to improve hemostasis in hemophilia.

Authors:  Raja Prince; Luca Bologna; Mirko Manetti; Daniela Melchiorre; Irene Rosa; Natacha Dewarrat; Silvia Suardi; Poorya Amini; José A Fernández; Laurent Burnier; Claudia Quarroz; Maria Desiré Reina Caro; Yasuhiro Matsumura; Johanna A Kremer Hovinga; John H Griffin; Hans-Uwe Simon; Lidia Ibba-Manneschi; François Saller; Sara Calzavarini; Anne Angelillo-Scherrer
Journal:  Blood       Date:  2018-01-09       Impact factor: 25.476

6.  Sucrose-Formulated Recombinant Factor VIII Dosing Flexibility in Prophylaxis Regimens: Experience from Postmarketing Surveillance Studies.

Authors:  Thomas J Humphries; Stephan Rauchensteiner; Claudia Tückmantel; Alexander Pieper; Monika Maas Enriquez; Prasad Mathew
Journal:  Adv Hematol       Date:  2015-08-19

7.  Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A.

Authors:  Brian R Long; Philippe Veron; Klaudia Kuranda; Romain Hardet; Nina Mitchell; Gregory M Hayes; Wing Yen Wong; Kelly Lau; Mingjin Li; M Benjamin Hock; Stephen J Zoog; Christian Vettermann; Federico Mingozzi; Becky Schweighardt
Journal:  Mol Ther       Date:  2020-12-10       Impact factor: 11.454

Review 8.  Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method.

Authors:  Erik Berntorp; Gerald Spotts; Lisa Patrone; Bruce M Ewenstein
Journal:  Biologics       Date:  2014-04-05

9.  Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy.

Authors:  F Shafer; L Smith; N Vendetti; P Rendo; M Carr
Journal:  Haemophilia       Date:  2013-11-29       Impact factor: 4.287

10.  Product type and other environmental risk factors for inhibitor development in severe hemophilia A.

Authors:  Flora Peyvandi; Isabella Garagiola
Journal:  Res Pract Thromb Haemost       Date:  2018-04-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.